nodes	percent_of_prediction	percent_of_DWPC	metapath
Palonosetron—CYP1A2—Carmustine—lymphatic system cancer	0.287	0.471	CbGbCtD
Palonosetron—CYP3A4—Cytarabine—lymphatic system cancer	0.103	0.168	CbGbCtD
Palonosetron—CYP3A4—Teniposide—lymphatic system cancer	0.101	0.166	CbGbCtD
Palonosetron—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0708	0.116	CbGbCtD
Palonosetron—CYP3A4—Vincristine—lymphatic system cancer	0.0487	0.0798	CbGbCtD
Palonosetron—Infection—Teniposide—lymphatic system cancer	0.00177	0.00456	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00176	0.00451	CcSEcCtD
Palonosetron—Tachycardia—Teniposide—lymphatic system cancer	0.00174	0.00448	CcSEcCtD
Palonosetron—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00173	0.00446	CcSEcCtD
Palonosetron—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00173	0.00444	CcSEcCtD
Palonosetron—Pruritus—Mechlorethamine—lymphatic system cancer	0.00171	0.0044	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00171	0.00439	CcSEcCtD
Palonosetron—Anorexia—Teniposide—lymphatic system cancer	0.0017	0.00437	CcSEcCtD
Palonosetron—Hypotension—Teniposide—lymphatic system cancer	0.00167	0.00428	CcSEcCtD
Palonosetron—Convulsion—Fludarabine—lymphatic system cancer	0.00166	0.00428	CcSEcCtD
Palonosetron—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00166	0.00426	CcSEcCtD
Palonosetron—Arthralgia—Fludarabine—lymphatic system cancer	0.00164	0.0042	CcSEcCtD
Palonosetron—Myalgia—Fludarabine—lymphatic system cancer	0.00164	0.0042	CcSEcCtD
Palonosetron—Discomfort—Fludarabine—lymphatic system cancer	0.00162	0.00415	CcSEcCtD
Palonosetron—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00159	0.00409	CcSEcCtD
Palonosetron—Dyspnoea—Teniposide—lymphatic system cancer	0.00159	0.00409	CcSEcCtD
Palonosetron—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00157	0.00403	CcSEcCtD
Palonosetron—Infection—Fludarabine—lymphatic system cancer	0.00156	0.004	CcSEcCtD
Palonosetron—Decreased appetite—Teniposide—lymphatic system cancer	0.00155	0.00399	CcSEcCtD
Palonosetron—Vomiting—Mechlorethamine—lymphatic system cancer	0.00154	0.00395	CcSEcCtD
Palonosetron—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00154	0.00395	CcSEcCtD
Palonosetron—Rash—Mechlorethamine—lymphatic system cancer	0.00153	0.00392	CcSEcCtD
Palonosetron—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00152	0.00392	CcSEcCtD
Palonosetron—Anorexia—Fludarabine—lymphatic system cancer	0.00149	0.00384	CcSEcCtD
Palonosetron—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00148	0.0038	CcSEcCtD
Palonosetron—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00146	0.00375	CcSEcCtD
Palonosetron—Chills—Bleomycin—lymphatic system cancer	0.00145	0.00373	CcSEcCtD
Palonosetron—Nausea—Mechlorethamine—lymphatic system cancer	0.00144	0.00369	CcSEcCtD
Palonosetron—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.00143	0.00368	CcSEcCtD
Palonosetron—Alopecia—Bleomycin—lymphatic system cancer	0.00143	0.00368	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00143	0.00367	CcSEcCtD
Palonosetron—Abdominal pain—Teniposide—lymphatic system cancer	0.00141	0.00362	CcSEcCtD
Palonosetron—Body temperature increased—Teniposide—lymphatic system cancer	0.00141	0.00362	CcSEcCtD
Palonosetron—Erythema—Bleomycin—lymphatic system cancer	0.00141	0.00362	CcSEcCtD
Palonosetron—Paraesthesia—Fludarabine—lymphatic system cancer	0.00141	0.00362	CcSEcCtD
Palonosetron—Dyspnoea—Fludarabine—lymphatic system cancer	0.0014	0.00359	CcSEcCtD
Palonosetron—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00139	0.00357	CcSEcCtD
Palonosetron—Dyspepsia—Fludarabine—lymphatic system cancer	0.00138	0.00355	CcSEcCtD
Palonosetron—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00138	0.00354	CcSEcCtD
Palonosetron—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00137	0.00353	CcSEcCtD
Palonosetron—Decreased appetite—Fludarabine—lymphatic system cancer	0.00136	0.0035	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00135	0.00348	CcSEcCtD
Palonosetron—Fatigue—Fludarabine—lymphatic system cancer	0.00135	0.00347	CcSEcCtD
Palonosetron—Pain—Fludarabine—lymphatic system cancer	0.00134	0.00345	CcSEcCtD
Palonosetron—Constipation—Fludarabine—lymphatic system cancer	0.00134	0.00345	CcSEcCtD
Palonosetron—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00134	0.00344	CcSEcCtD
Palonosetron—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00133	0.00342	CcSEcCtD
Palonosetron—Respiratory failure—Methotrexate—lymphatic system cancer	0.00133	0.00341	CcSEcCtD
Palonosetron—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00133	0.00341	CcSEcCtD
Palonosetron—Urethral disorder—Vincristine—lymphatic system cancer	0.00132	0.0034	CcSEcCtD
Palonosetron—Eye disorder—Carmustine—lymphatic system cancer	0.00132	0.00339	CcSEcCtD
Palonosetron—Hypersensitivity—Teniposide—lymphatic system cancer	0.00131	0.00338	CcSEcCtD
Palonosetron—Anaemia—Bleomycin—lymphatic system cancer	0.0013	0.00335	CcSEcCtD
Palonosetron—Asthenia—Teniposide—lymphatic system cancer	0.00128	0.00329	CcSEcCtD
Palonosetron—Pruritus—Teniposide—lymphatic system cancer	0.00126	0.00324	CcSEcCtD
Palonosetron—Arrhythmia—Carmustine—lymphatic system cancer	0.00126	0.00324	CcSEcCtD
Palonosetron—Cardiac disorder—Vincristine—lymphatic system cancer	0.00125	0.00322	CcSEcCtD
Palonosetron—Alopecia—Carmustine—lymphatic system cancer	0.00125	0.00321	CcSEcCtD
Palonosetron—Body temperature increased—Fludarabine—lymphatic system cancer	0.00124	0.00319	CcSEcCtD
Palonosetron—Mental disorder—Carmustine—lymphatic system cancer	0.00124	0.00318	CcSEcCtD
Palonosetron—Erythema—Carmustine—lymphatic system cancer	0.00123	0.00316	CcSEcCtD
Palonosetron—Malnutrition—Carmustine—lymphatic system cancer	0.00123	0.00316	CcSEcCtD
Palonosetron—Angiopathy—Vincristine—lymphatic system cancer	0.00122	0.00314	CcSEcCtD
Palonosetron—Diarrhoea—Teniposide—lymphatic system cancer	0.00122	0.00314	CcSEcCtD
Palonosetron—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00122	0.00312	CcSEcCtD
Palonosetron—Myalgia—Bleomycin—lymphatic system cancer	0.0012	0.00308	CcSEcCtD
Palonosetron—Alopecia—Vincristine—lymphatic system cancer	0.00119	0.00306	CcSEcCtD
Palonosetron—Discomfort—Bleomycin—lymphatic system cancer	0.00119	0.00305	CcSEcCtD
Palonosetron—Mental disorder—Vincristine—lymphatic system cancer	0.00118	0.00304	CcSEcCtD
Palonosetron—Chills—Mitoxantrone—lymphatic system cancer	0.00118	0.00303	CcSEcCtD
Palonosetron—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00117	0.00302	CcSEcCtD
Palonosetron—Alopecia—Mitoxantrone—lymphatic system cancer	0.00116	0.00298	CcSEcCtD
Palonosetron—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00116	0.00297	CcSEcCtD
Palonosetron—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00115	0.00295	CcSEcCtD
Palonosetron—Erythema—Mitoxantrone—lymphatic system cancer	0.00114	0.00294	CcSEcCtD
Palonosetron—Infection—Bleomycin—lymphatic system cancer	0.00114	0.00294	CcSEcCtD
Palonosetron—Anaemia—Carmustine—lymphatic system cancer	0.00114	0.00292	CcSEcCtD
Palonosetron—Vomiting—Teniposide—lymphatic system cancer	0.00113	0.00292	CcSEcCtD
Palonosetron—Asthenia—Fludarabine—lymphatic system cancer	0.00113	0.00289	CcSEcCtD
Palonosetron—Rash—Teniposide—lymphatic system cancer	0.00113	0.00289	CcSEcCtD
Palonosetron—Dermatitis—Teniposide—lymphatic system cancer	0.00112	0.00289	CcSEcCtD
Palonosetron—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00112	0.00288	CcSEcCtD
Palonosetron—Headache—Teniposide—lymphatic system cancer	0.00112	0.00287	CcSEcCtD
Palonosetron—Pruritus—Fludarabine—lymphatic system cancer	0.00111	0.00285	CcSEcCtD
Palonosetron—Anorexia—Bleomycin—lymphatic system cancer	0.0011	0.00282	CcSEcCtD
Palonosetron—Anaemia—Vincristine—lymphatic system cancer	0.00109	0.00279	CcSEcCtD
Palonosetron—Hypotension—Bleomycin—lymphatic system cancer	0.00107	0.00276	CcSEcCtD
Palonosetron—Diarrhoea—Fludarabine—lymphatic system cancer	0.00107	0.00276	CcSEcCtD
Palonosetron—Convulsion—Carmustine—lymphatic system cancer	0.00107	0.00274	CcSEcCtD
Palonosetron—Hypertension—Carmustine—lymphatic system cancer	0.00106	0.00273	CcSEcCtD
Palonosetron—Nausea—Teniposide—lymphatic system cancer	0.00106	0.00272	CcSEcCtD
Palonosetron—Anaemia—Mitoxantrone—lymphatic system cancer	0.00106	0.00272	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00105	0.00269	CcSEcCtD
Palonosetron—Myalgia—Carmustine—lymphatic system cancer	0.00105	0.00269	CcSEcCtD
Palonosetron—Anxiety—Carmustine—lymphatic system cancer	0.00104	0.00268	CcSEcCtD
Palonosetron—Paraesthesia—Bleomycin—lymphatic system cancer	0.00103	0.00265	CcSEcCtD
Palonosetron—Dyspnoea—Bleomycin—lymphatic system cancer	0.00103	0.00263	CcSEcCtD
Palonosetron—Convulsion—Vincristine—lymphatic system cancer	0.00102	0.00261	CcSEcCtD
Palonosetron—Hypertension—Vincristine—lymphatic system cancer	0.00101	0.0026	CcSEcCtD
Palonosetron—Decreased appetite—Bleomycin—lymphatic system cancer	0.001	0.00257	CcSEcCtD
Palonosetron—Myalgia—Vincristine—lymphatic system cancer	0.000999	0.00257	CcSEcCtD
Palonosetron—Infection—Carmustine—lymphatic system cancer	0.000997	0.00256	CcSEcCtD
Palonosetron—Vomiting—Fludarabine—lymphatic system cancer	0.000997	0.00256	CcSEcCtD
Palonosetron—Convulsion—Mitoxantrone—lymphatic system cancer	0.000991	0.00255	CcSEcCtD
Palonosetron—Rash—Fludarabine—lymphatic system cancer	0.000989	0.00254	CcSEcCtD
Palonosetron—Dermatitis—Fludarabine—lymphatic system cancer	0.000988	0.00254	CcSEcCtD
Palonosetron—Hypertension—Mitoxantrone—lymphatic system cancer	0.000987	0.00254	CcSEcCtD
Palonosetron—Pain—Bleomycin—lymphatic system cancer	0.000983	0.00253	CcSEcCtD
Palonosetron—Headache—Fludarabine—lymphatic system cancer	0.000982	0.00252	CcSEcCtD
Palonosetron—Tachycardia—Carmustine—lymphatic system cancer	0.00098	0.00252	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000977	0.00251	CcSEcCtD
Palonosetron—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000973	0.0025	CcSEcCtD
Palonosetron—Myalgia—Mitoxantrone—lymphatic system cancer	0.000973	0.0025	CcSEcCtD
Palonosetron—Anxiety—Mitoxantrone—lymphatic system cancer	0.00097	0.00249	CcSEcCtD
Palonosetron—Discomfort—Mitoxantrone—lymphatic system cancer	0.000962	0.00247	CcSEcCtD
Palonosetron—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000958	0.00246	CcSEcCtD
Palonosetron—Anorexia—Carmustine—lymphatic system cancer	0.000957	0.00246	CcSEcCtD
Palonosetron—Infection—Vincristine—lymphatic system cancer	0.000952	0.00245	CcSEcCtD
Palonosetron—Nervous system disorder—Vincristine—lymphatic system cancer	0.00094	0.00241	CcSEcCtD
Palonosetron—Hypotension—Carmustine—lymphatic system cancer	0.000938	0.00241	CcSEcCtD
Palonosetron—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000933	0.0024	CcSEcCtD
Palonosetron—Nausea—Fludarabine—lymphatic system cancer	0.000932	0.00239	CcSEcCtD
Palonosetron—Infection—Mitoxantrone—lymphatic system cancer	0.000927	0.00238	CcSEcCtD
Palonosetron—Shock—Mitoxantrone—lymphatic system cancer	0.000918	0.00236	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000914	0.00235	CcSEcCtD
Palonosetron—Anorexia—Vincristine—lymphatic system cancer	0.000913	0.00235	CcSEcCtD
Palonosetron—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000911	0.00234	CcSEcCtD
Palonosetron—Body temperature increased—Bleomycin—lymphatic system cancer	0.000909	0.00234	CcSEcCtD
Palonosetron—Insomnia—Carmustine—lymphatic system cancer	0.000908	0.00233	CcSEcCtD
Palonosetron—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000906	0.00233	CcSEcCtD
Palonosetron—Paraesthesia—Carmustine—lymphatic system cancer	0.000901	0.00232	CcSEcCtD
Palonosetron—Hypotension—Vincristine—lymphatic system cancer	0.000895	0.0023	CcSEcCtD
Palonosetron—Dyspnoea—Carmustine—lymphatic system cancer	0.000895	0.0023	CcSEcCtD
Palonosetron—Somnolence—Carmustine—lymphatic system cancer	0.000892	0.00229	CcSEcCtD
Palonosetron—Anorexia—Mitoxantrone—lymphatic system cancer	0.000889	0.00229	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000873	0.00224	CcSEcCtD
Palonosetron—Decreased appetite—Carmustine—lymphatic system cancer	0.000872	0.00224	CcSEcCtD
Palonosetron—Hypotension—Mitoxantrone—lymphatic system cancer	0.000872	0.00224	CcSEcCtD
Palonosetron—Insomnia—Vincristine—lymphatic system cancer	0.000867	0.00223	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000867	0.00223	CcSEcCtD
Palonosetron—Paraesthesia—Vincristine—lymphatic system cancer	0.00086	0.00221	CcSEcCtD
Palonosetron—Constipation—Carmustine—lymphatic system cancer	0.000858	0.00221	CcSEcCtD
Palonosetron—Pain—Carmustine—lymphatic system cancer	0.000858	0.00221	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00085	0.00218	CcSEcCtD
Palonosetron—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000847	0.00218	CcSEcCtD
Palonosetron—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000838	0.00215	CcSEcCtD
Palonosetron—Decreased appetite—Vincristine—lymphatic system cancer	0.000833	0.00214	CcSEcCtD
Palonosetron—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000832	0.00214	CcSEcCtD
Palonosetron—Somnolence—Mitoxantrone—lymphatic system cancer	0.00083	0.00213	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000827	0.00213	CcSEcCtD
Palonosetron—Fatigue—Vincristine—lymphatic system cancer	0.000826	0.00212	CcSEcCtD
Palonosetron—Asthenia—Bleomycin—lymphatic system cancer	0.000825	0.00212	CcSEcCtD
Palonosetron—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000821	0.00211	CcSEcCtD
Palonosetron—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000821	0.00211	CcSEcCtD
Palonosetron—Pain—Vincristine—lymphatic system cancer	0.000819	0.00211	CcSEcCtD
Palonosetron—Constipation—Vincristine—lymphatic system cancer	0.000819	0.00211	CcSEcCtD
Palonosetron—Pruritus—Bleomycin—lymphatic system cancer	0.000814	0.00209	CcSEcCtD
Palonosetron—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000811	0.00208	CcSEcCtD
Palonosetron—Fatigue—Mitoxantrone—lymphatic system cancer	0.000804	0.00207	CcSEcCtD
Palonosetron—Constipation—Mitoxantrone—lymphatic system cancer	0.000798	0.00205	CcSEcCtD
Palonosetron—Pain—Mitoxantrone—lymphatic system cancer	0.000798	0.00205	CcSEcCtD
Palonosetron—Abdominal pain—Carmustine—lymphatic system cancer	0.000793	0.00204	CcSEcCtD
Palonosetron—Body temperature increased—Carmustine—lymphatic system cancer	0.000793	0.00204	CcSEcCtD
Palonosetron—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000783	0.00201	CcSEcCtD
Palonosetron—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000763	0.00196	CcSEcCtD
Palonosetron—Abdominal pain—Vincristine—lymphatic system cancer	0.000757	0.00195	CcSEcCtD
Palonosetron—Body temperature increased—Vincristine—lymphatic system cancer	0.000757	0.00195	CcSEcCtD
Palonosetron—Hypersensitivity—Carmustine—lymphatic system cancer	0.000739	0.0019	CcSEcCtD
Palonosetron—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000738	0.0019	CcSEcCtD
Palonosetron—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000738	0.0019	CcSEcCtD
Palonosetron—Vomiting—Bleomycin—lymphatic system cancer	0.000731	0.00188	CcSEcCtD
Palonosetron—Rash—Bleomycin—lymphatic system cancer	0.000725	0.00186	CcSEcCtD
Palonosetron—Dermatitis—Bleomycin—lymphatic system cancer	0.000724	0.00186	CcSEcCtD
Palonosetron—Asthenia—Carmustine—lymphatic system cancer	0.00072	0.00185	CcSEcCtD
Palonosetron—Hypersensitivity—Vincristine—lymphatic system cancer	0.000706	0.00181	CcSEcCtD
Palonosetron—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000689	0.00177	CcSEcCtD
Palonosetron—Epistaxis—Methotrexate—lymphatic system cancer	0.000688	0.00177	CcSEcCtD
Palonosetron—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000687	0.00177	CcSEcCtD
Palonosetron—Asthenia—Vincristine—lymphatic system cancer	0.000687	0.00177	CcSEcCtD
Palonosetron—Diarrhoea—Carmustine—lymphatic system cancer	0.000687	0.00176	CcSEcCtD
Palonosetron—Nausea—Bleomycin—lymphatic system cancer	0.000683	0.00176	CcSEcCtD
Palonosetron—Asthenia—Mitoxantrone—lymphatic system cancer	0.000669	0.00172	CcSEcCtD
Palonosetron—Dizziness—Carmustine—lymphatic system cancer	0.000664	0.00171	CcSEcCtD
Palonosetron—Diarrhoea—Vincristine—lymphatic system cancer	0.000656	0.00168	CcSEcCtD
Palonosetron—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000646	0.00166	CcSEcCtD
Palonosetron—Urethral disorder—Methotrexate—lymphatic system cancer	0.000641	0.00165	CcSEcCtD
Palonosetron—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000638	0.00164	CcSEcCtD
Palonosetron—Vomiting—Carmustine—lymphatic system cancer	0.000638	0.00164	CcSEcCtD
Palonosetron—Dizziness—Vincristine—lymphatic system cancer	0.000634	0.00163	CcSEcCtD
Palonosetron—Rash—Carmustine—lymphatic system cancer	0.000633	0.00163	CcSEcCtD
Palonosetron—Dermatitis—Carmustine—lymphatic system cancer	0.000632	0.00162	CcSEcCtD
Palonosetron—Headache—Carmustine—lymphatic system cancer	0.000629	0.00162	CcSEcCtD
Palonosetron—Eye disorder—Methotrexate—lymphatic system cancer	0.000612	0.00157	CcSEcCtD
Palonosetron—Tinnitus—Methotrexate—lymphatic system cancer	0.00061	0.00157	CcSEcCtD
Palonosetron—Vomiting—Vincristine—lymphatic system cancer	0.000609	0.00157	CcSEcCtD
Palonosetron—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000607	0.00156	CcSEcCtD
Palonosetron—Rash—Vincristine—lymphatic system cancer	0.000604	0.00155	CcSEcCtD
Palonosetron—Dermatitis—Vincristine—lymphatic system cancer	0.000604	0.00155	CcSEcCtD
Palonosetron—Headache—Vincristine—lymphatic system cancer	0.0006	0.00154	CcSEcCtD
Palonosetron—Nausea—Carmustine—lymphatic system cancer	0.000596	0.00153	CcSEcCtD
Palonosetron—Angiopathy—Methotrexate—lymphatic system cancer	0.000594	0.00153	CcSEcCtD
Palonosetron—Vomiting—Mitoxantrone—lymphatic system cancer	0.000593	0.00152	CcSEcCtD
Palonosetron—Immune system disorder—Methotrexate—lymphatic system cancer	0.000591	0.00152	CcSEcCtD
Palonosetron—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00059	0.00152	CcSEcCtD
Palonosetron—Rash—Mitoxantrone—lymphatic system cancer	0.000588	0.00151	CcSEcCtD
Palonosetron—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000588	0.00151	CcSEcCtD
Palonosetron—Chills—Methotrexate—lymphatic system cancer	0.000587	0.00151	CcSEcCtD
Palonosetron—Headache—Mitoxantrone—lymphatic system cancer	0.000585	0.0015	CcSEcCtD
Palonosetron—Alopecia—Methotrexate—lymphatic system cancer	0.000578	0.00149	CcSEcCtD
Palonosetron—Mental disorder—Methotrexate—lymphatic system cancer	0.000573	0.00147	CcSEcCtD
Palonosetron—Erythema—Methotrexate—lymphatic system cancer	0.00057	0.00146	CcSEcCtD
Palonosetron—Malnutrition—Methotrexate—lymphatic system cancer	0.00057	0.00146	CcSEcCtD
Palonosetron—Nausea—Vincristine—lymphatic system cancer	0.000569	0.00146	CcSEcCtD
Palonosetron—Dysgeusia—Methotrexate—lymphatic system cancer	0.000558	0.00143	CcSEcCtD
Palonosetron—Nausea—Mitoxantrone—lymphatic system cancer	0.000554	0.00142	CcSEcCtD
Palonosetron—Anaemia—Methotrexate—lymphatic system cancer	0.000526	0.00135	CcSEcCtD
Palonosetron—Convulsion—Methotrexate—lymphatic system cancer	0.000494	0.00127	CcSEcCtD
Palonosetron—Myalgia—Methotrexate—lymphatic system cancer	0.000485	0.00125	CcSEcCtD
Palonosetron—Arthralgia—Methotrexate—lymphatic system cancer	0.000485	0.00125	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000482	0.00124	CcSEcCtD
Palonosetron—Discomfort—Methotrexate—lymphatic system cancer	0.000479	0.00123	CcSEcCtD
Palonosetron—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000465	0.00119	CcSEcCtD
Palonosetron—Infection—Methotrexate—lymphatic system cancer	0.000462	0.00119	CcSEcCtD
Palonosetron—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000456	0.00117	CcSEcCtD
Palonosetron—Skin disorder—Methotrexate—lymphatic system cancer	0.000452	0.00116	CcSEcCtD
Palonosetron—Anorexia—Methotrexate—lymphatic system cancer	0.000443	0.00114	CcSEcCtD
Palonosetron—Hypotension—Methotrexate—lymphatic system cancer	0.000434	0.00112	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000424	0.00109	CcSEcCtD
Palonosetron—Insomnia—Methotrexate—lymphatic system cancer	0.00042	0.00108	CcSEcCtD
Palonosetron—Paraesthesia—Methotrexate—lymphatic system cancer	0.000417	0.00107	CcSEcCtD
Palonosetron—Dyspnoea—Methotrexate—lymphatic system cancer	0.000414	0.00107	CcSEcCtD
Palonosetron—Somnolence—Methotrexate—lymphatic system cancer	0.000413	0.00106	CcSEcCtD
Palonosetron—Dyspepsia—Methotrexate—lymphatic system cancer	0.000409	0.00105	CcSEcCtD
Palonosetron—Decreased appetite—Methotrexate—lymphatic system cancer	0.000404	0.00104	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000401	0.00103	CcSEcCtD
Palonosetron—Fatigue—Methotrexate—lymphatic system cancer	0.000401	0.00103	CcSEcCtD
Palonosetron—Pain—Methotrexate—lymphatic system cancer	0.000398	0.00102	CcSEcCtD
Palonosetron—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00038	0.000977	CcSEcCtD
Palonosetron—Abdominal pain—Methotrexate—lymphatic system cancer	0.000368	0.000944	CcSEcCtD
Palonosetron—Body temperature increased—Methotrexate—lymphatic system cancer	0.000368	0.000944	CcSEcCtD
Palonosetron—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000343	0.00088	CcSEcCtD
Palonosetron—Asthenia—Methotrexate—lymphatic system cancer	0.000334	0.000857	CcSEcCtD
Palonosetron—Pruritus—Methotrexate—lymphatic system cancer	0.000329	0.000845	CcSEcCtD
Palonosetron—Diarrhoea—Methotrexate—lymphatic system cancer	0.000318	0.000817	CcSEcCtD
Palonosetron—Dizziness—Methotrexate—lymphatic system cancer	0.000307	0.00079	CcSEcCtD
Palonosetron—Vomiting—Methotrexate—lymphatic system cancer	0.000296	0.00076	CcSEcCtD
Palonosetron—Rash—Methotrexate—lymphatic system cancer	0.000293	0.000753	CcSEcCtD
Palonosetron—Dermatitis—Methotrexate—lymphatic system cancer	0.000293	0.000753	CcSEcCtD
Palonosetron—Headache—Methotrexate—lymphatic system cancer	0.000291	0.000748	CcSEcCtD
Palonosetron—Nausea—Methotrexate—lymphatic system cancer	0.000276	0.00071	CcSEcCtD
